Of note, RA patients are being recruited for a clinical trial to track the potential effects of the Jak inhibitor tofacitinib on pain sensitization, and as a secondary outcome, investigators will be monitoring plasma levels of four miRNAs implicated in Jak/STAT signaling and RA pathogenesis, including miR-21 (NCT03815578). Here, SOAT1 is linked to rheumatoid arthritis.